# DESCRIPTION

- introduce malignant melanoma
- motivate need for predicting course of disease
- summarize current staging methods
- discuss limitations of current staging methods
- review prior art on molecular markers
- highlight lack of predictive molecular profiles
- define predicting the course of disease
- explain favourable and unfavourable progression/outcome
- define malignant melanoma and its staging
- define melanoma cells and biomarkers
- incorporate prior art by reference
- define terms
- define "determining the presence"
- define "determining the amount"
- define "decreased amount"
- define "increased amount"
- define "expression level"
- describe methods for determining expression levels on protein level
- describe methods for determining expression levels on nucleic acid level
- describe RT-PCR
- describe real-time PCR
- describe detection of mutations and variations
- describe non-limiting examples for nucleic acid amplification assays
- describe sequencing assays
- describe hybridization assays
- define "at least five biomarkers"
- define "reference marker"
- describe normalizing values of biomarker amounts
- describe strategies for normalisation
- describe mathematically dividing expression values
- describe subtracting expression values
- define microarray analysis normalisation techniques
- define MTAP protein
- define PTEN protein
- define Bax protein
- define Bcl-X protein
- define Î²-Catenin protein
- define CD20 protein
- define Cox-2 protein
- define CD49d protein
- define MLH1 protein
- describe association of markers with disease course
- describe method for predicting disease outcome
- define prognostic score calculation
- motivate reference score
- describe score interpretation
- introduce alternative score calculation
- motivate initial determination of biomarkers
- describe correlation of biomarkers with disease progression
- introduce simplified score calculation
- motivate preferred embodiment with PTEN and/or MTAP
- describe therapeutic relevance of MTAP and PTEN
- introduce preferred embodiment with at least seven biomarkers
- describe validation of seven-marker signature
- motivate biomarker analysis
- describe biomarker set
- summarize patient study results
- describe pharmaceutical composition preparation method
- define pharmaceutical composition
- describe composition administration
- determine dosage regimen
- describe therapeutic compound selection
- define antibody
- describe antibody production techniques
- define aptamer
- describe aptamer types
- describe aptamer advantages
- define peptide and protein
- define siRNA
- describe structure of siRNA
- describe function of siRNA
- describe delivery of siRNA
- introduce shRNA
- describe function of shRNA
- describe synthesis of si/shRNA
- introduce miRNA
- describe function of miRNA
- introduce ribozyme
- describe function of ribozyme
- describe construction of hammerhead ribozymes
- introduce aptamer-ribozyme combination
- define antisense nucleic acid molecule
- describe function of antisense molecule
- define small molecule
- describe characteristics of small molecule
- introduce modified versions of therapeutic compounds
- describe tailored pharmaceutical composition
- define biomarkers
- describe preferred embodiments of biomarkers
- define primary tumor
- define lymph node
- describe sample types
- describe methods for determining biomarkers
- describe kit for predicting disease course
- describe kit components
- describe additional kit components
- describe pharmaceutical composition
- define inhibitor
- describe inhibitor classes
- describe preferred embodiments of inhibitors
- describe specific inhibitors

## Materials and Methods

### Tissue Microarrays (TMAs)

- construct TMAs from primary melanoma material

### Immunohistochemical Analysis

- screen for protein expression using IHC protocols
- evaluate cytoplasmic and nuclear markers

### Statistical Analysis

- estimate statistical power versus total sample size
- handle missing values in the design matrix
- assess prognostic power of markers using Cox models
- calculate risk score using linear combination of Cox coefficients
- validate risk score using Kaplan-Meier estimators and log-rank test

## EXAMPLE 2

### The Nine-Marker Signature and Survival

- identify nine markers correlated with death from any cause
- describe characteristics of patients with high-risk and low-risk signatures
- validate signature using cross-validation experiments

## EXAMPLE 3

### The Seven-Marker Signature and Survival

- reduce nine-marker signature to seven markers
- validate seven-marker signature using survival analysis

## EXAMPLE 4

### Validation of the Seven-Marker Signature on an External Test Cohort

- validate seven-marker signature on external test cohort

## EXAMPLE 5

### The Six-Marker Signature and Survival

- validate six-marker signature using survival analysis

## EXAMPLE 6

### The Five-Marker Signature and Survival

- validate five-marker signature using survival analysis

